Advancements in ocular drug delivery

Veterinary Ophthalmology

Volumn 13, Issue 6, 2010, Pages 395-406

  Weiner, Alan L ^a   Gilger, Brian C ^b  

^a ALCON RESEARCH LTD   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Drug delivery; Eye; Implants; Therapeutics; Veterinary

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; EYE DISEASE; PROSTHESES AND ORTHOSES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EYE DISEASES; PROSTHESES AND IMPLANTS;

EID: 78349294542     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2010.00835.x     Document Type: Article

References (102)

1. Weiner A. Drug delivery systems in ophthalmic applications. In: Ocular Therapeutics: Eye on New Discoveries. (eds Yorio T, Clark A, Wax M) Elsevier Press/Academic Press, New York, 2006; 7-43.
2. Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery. Current Opinion in Molecular Therapeutics 2004; 6: 195-205.
3. Gilger BC, Salmon JH, Wilkie DA et al. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Investigative Ophthalmology and Visual Science 2006; 47: 2596-2605.
4. Gilger BC, Wilkie DA, Davidson MG et al. Use of an intravitreal sustained-release cyclosporine delivery device for treatment of equine recurrent uveitis. American Journal of Veterinary Research 2001; 62: 1892-1896.
5. Gokulgandhi M, Modi D, Parikh J. In situ gel systems for ocular drug delivery: a review. Drug Delivery Technology 2007; 7: 30-37.
6. Abelson M, Protzko E, Shapiro A. A Randomized Trial Assessing Microbial Eradication and Clinical Efficacy of 1% Azithromycin Ophthalmic Solution vs. Tobramycin in Adult Subjects With Bacterial Conjunctivitis. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.
7. Colin J. Ganciclovir ophthalmic gel, 0.15%; a valuable tool for treating ocular herpes. Clinical Ophthalmology 2007; 1: 441-453.
8. Rouland J-F, Morel-Mandrino P, Elena P-P et al. Timolol 0.1% Gel (Nyogel 0.1%) once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica 2002; 216: 449-454.
9. Kalam M, Sultana Y, Samad A et al. Gelrite-based in vitro gelation ophthalmic drug delivery system of gatifloxacin. Journal of Dispersion Science and Technology 2008; 29: 89-96.
10. Scoper S, Kabat A, Owen G et al. Ocular distribution, bactericidal activity and settling characteristics of TobrDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension. Advances in Therapeutics 2008; 25: 77-88.
11. McCormick C, Caballera A, Tang A et al. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental pseudomonas keratitis. Current Medical Research Opinions 2008; 24: 1569-1575.
12. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Advanced Drug Delivery Reviews 2005; 57: 1595-1639.
13. Liu Z, Li J, Nie S et al. Study of an alginate/HPMC based in situ gelling ophthalmic delivery system for gatifloxacin. International Journal of Pharmaceutics 2006; 315: 12-17.
14. Abraham S, Furtado S, Bharath S et al. Sustained ophthalmic delivery of ofloxacin from an ion-activated in situ gelling system. Pakistani Journal of Pharmaceutical Science 2009; 22: 175-179.
15. Hassan M. Long acting ophthalmic gel formulations of atenolol. Drug Development and Industrial Pharmacy 2007; 33: 1192-1198.
16. Pandit J, Bharathi D, Srinatha A et al. Long acting ophthalmic formulation of indomethacin: evaluation of alginate gel systems. Indian Journal of Pharmaceutical Science 2007; 69: 37-40.
17. Wong T, Shen Y, Jing-Jang C et al. 5-FU Combined with Hyaluronic Acid: Effect on Drug Release Rate. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.
18. Spitzer M, Kaczmarek R, Sierra A et al. Sodium Hyaluronate Gel (Healon and Healon 5) as Drug Release System for Hydrophilic Steroid Formulation in Ophthalmic Surgery: Release Kinetics and Antiproliferative Potential. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.
19. Alonso M, Sanchez A. The potential of chitosan in ocular drug delivery. Journal of Pharmacy and Pharmacology 2003; 55: 1451-1463.
20. Utecht R, Kloster K, Downey T et al. Novel biomaterials and a method for making and using same. US Patent 20080200948, 2008.
21. Verestiuc L, Nastasescu O, Barbu E et al. Functionalized chitosan/NIPAM (HEMA) hybrid polymer networks as inserts for ocular drug delivery: synthesis, in vitro assessment, and in vivo evaluation. Journal of Biomedical Materials Research Part A 2006; 77: 726-735.
22. Cao Y, Zhang C, Shen W et al. Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery. Journal of Controlled Release 2007; 120: 186-194.
23. Krauland A, Hoffer M, Bernkop-Schnurch A. Viscoelastic properties of a new in situ gelling thiolated chitosan conjugate. Drug Development and Industrial Pharmacy 2005; 31: 885-893.
24. Bhattarai N, Ramay H, Gunn J et al. PEG-grafted chitosan as an injectable thermosensitive hydrogel for sustained protein release. Journal of Controlled Release 2005; 103: 609-624.
25. De La Fuente M, Seijo B, Alonso M. Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Therapy 2008; 15: 668-676.
26. Hongyok T, Chae J, Shin Y et al. Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin b-induced dry eye. Archives of Ophthalmology 2009; 127: 525-532.
27. Kao H, Lin H, Lo Y et al. Characterization of pilocarpine-loaded chitosan/carbopol nanoparticles. Journal of Pharmacy and Pharmacology 2006; 58: 179-186.
28. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a thermosensitive chitosan/poloxamer in situ gel for ocular delivery of ciprofloxacin. The Open Drug Delivery Journal 2008; 2: 61-70.
29. Maa W-D, Xua H, Wanga C et al. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. International Journal of Pharmaceutics 2008; 350: 247-256.
30. Kim E-Y, Gao Z-G, Park J-S et al. rhEGF/HP-beta-CD complex in poloxamer gel for ophthalmic delivery. International Journal of Pharmaceutics 2002; 233: 159-167.
31. Yoo M-K, Cho K-Y, Song H-H et al. Release of ciprofloxacin from chondroitin 6-sulfate-graft-poloxamer hydrogel in vitro for ophthalmic drug delivery. Drug Development and Industrial Pharmacy 2005; 31: 455-463.
32. Desai S, Blanchard J. Pluronic F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Delivery 2000; 7: 201-207.
33. Rupenthal I, Green C, Hassan I et al. Investigating the precorneal residence time of ophthalmic in-situ gelling systems using gamma scintigraphy (abstract). 35th Annual Meeting and Exposition of the Controlled Release Society, 2008.
34. Liu Q, Wang Y. Development of an ex vivo method for evaluation of precorneal residence of topical ophthalmic formulations. AAPS PharmSciTech 2009; 10: 786-805.
35. Ke T, Graff G, Spellman J et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24: 371-384.
36. Kern T, Miller C, Du Y et al. Topical Administration of Nepafenac Inhibits the Early Stages of Diabetic Retinopathy. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2005.
37. Kaur I. Role of cyclodextrins in ophthalmics. Current Drug Delivery 2004; 1: 351-360.
38. Patravale V, Date A, Kulkarni R. Nanosuspensions: a promising drug delivery strategy. Journal of Pharmacy and Pharmacology 2004; 56: 827-840.
39. Eljarrat-Binstock E, Domb AJ. Iontophoresis: a non-invasive ocular drug delivery. Journal of Controlled Release 2006; 110: 479-489.
40. Bejjani R, Andrieu C, Bloquel C. Electrically assisted ocular gene therapy. Survey of Ophthalmology 2007; 52: 196-208.
41. Eljarrat-Binstock E, Orucov F, Frucht-Pery J et al. Methylprednisolone delivery to the back of the eye using hydrogel iontophoresis. Journal of Ocular Pharmacology and Therapeutics 2008; 24: 344-350.
42. Jiang J, Gill HS, Ghate D et al. Coated microneedles for drug delivery to the eye. Investigative Ophthalmology and Visual Science 2007; 48: 4038-4043.
43. Jiang J, Moore JS, Edelhauser HF et al. Intrascleral drug delivery to the eye using hollow microneedles. Pharmaceutical Research 2009; 26: 395-403.
44. McAllister D, Allen M, Prausnitz M. Microfabricated microneedles for gene and drug delivery. Annual Review of Biomedical Engineering 2000; 2: 289-313.
45. Prausnitz MR. Use of Microneedles for Drug Delivery. ARVO Summer Research Conference. NIH, Bethesda, MD, 2009.
46. Ciolino JB, Dohlman CH, Kohane DS. Contact lenses for drug delivery. Seminars in Ophthalmology 2009; 24: 156-160.
47. Ciolino JB, Hoare TR, Iwata NG et al. A drug-eluting contact lens. Investigative Ophthalmology and Visual Science 2009; 50: 3346-3352.
48. Xu J, Li X, Sun F. Cyclodextrin-containing hydrogels for contact lenses as a platform for drug incorporation and release. Acta Biomaterialia 2010; 6: 486-489.
49. Kahn M. Bioavailability of vitamin B using a small-volume nebulizer ophthalmic drug delivery system. Clinical and Experimental Ophthalmology 2005; 33: 402-407.
50. Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicologic Pathology 2008; 36: 49-62.
51. Hsu J. Drug delivery methods for posterior segment disease. Current Opinion in Ophthalmology 2007; 18: 235-239.
52. Edwards RS. A comparative study of Ocusert Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma. Current Medical Research and Opinion 1997; 13: 501-509.
53. Kovach J, Schwartz S. Novel pharmacologic approaches for the management of diabetic retinopathy. Molecular and Cellular Pharmacology 2009; 1: 222-227.
54. Shin JP, Park YC, Oh JH et al. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis. Journal of Ocular Pharmacology and Therapeutics 2009; 25: 201-208.
55. Sakurai E, Nozaki M, Okabe K et al. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Investigative Ophthalmology and Visual Science 2003; 44: 4845-4852.
56. Jaffe GJ. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. American Journal of Ophthalmology 2008; 145: 667-675.
57. Charles NC, Steiner GC. Ganciclovir intraocular implant. A clinicopathologic study. Ophthalmology 1996; 103: 416-421.
58. Anand R. Treatment of cytomegalovirus retinitis with the intraocular ganciclovir implant. Current Opinion in Ophthalmology 1997; 8: 8-14.
59. Kappel PJ, Charonis AC, Holland GN et al. Outcomes associated with ganciclovir implants in patients with AIDS-related cytomegalovirus retinitis. Ophthalmology 2006; 113: 683, e681-e688.
60. Gilger BC, Malok E, Stewart T et al. Long-term effect on the equine eye of an intravitreal device used for sustained release of cyclosporine A. Veterinary Ophthalmology 2000; 3: 105-110.
61. Gilger BC, Malok E, Stewart T et al. Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. Veterinary Immunology and Immunopathology 2000; 76: 239-255.
62. Jaffe GJ, McCallum RM, Branchaud B et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005; 112: 1192-1198.
63. Jaffe GJ, Martin D, Callanan D et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027.
64. Sieving PA, Caruso RC, Tao W et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 3896-3901.
65. Tao W, Wen R, Goddard MB et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Investigative Ophthalmology and Visual Science 2002; 43: 3292-3298.
66. Williams G, Tao W. A Phase II Study of Encapsulated CNTF Secreting Cell Implant (NT-501) in Patients With Visual Acuity Impairment Associated With Atrophic Macular Degeneration. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2009.
67. Mello-Filho PA, Guven D, Beeley NR et al. Helical intravitreal triamcinolone acetonide implant: a 6-month surgical feasibility study in rabbits. Ophthalmic Surgery, Lasers and Imaging 2009; 40: 160-168.
68. Blair MJ, Gionfriddo JR, Polazzi LM et al. Subconjunctivally implanted micro-osmotic pumps for continuous ocular treatment in horses. American Journal of Veterinary Research 1999; 60: 1102-1105.
69. Okabe K, Kimura H, Okabe J et al. Effect of benzalkonium chloride on transscleral drug delivery. Investigative Ophthalmology and Visual Science 2005; 46: 703-708.
70. Soltanpour D. Method and apparatus for controlling intraocular pressure. US Patent 6168575, 2001.
71. Meng E, Tai Y-C, Humayun M et al. MEMS device and method for delivery of therapeutic agents. U.S. Patent Application 20080039792, 2008.
72. Lobl T, Nagy A, Pananen J et al. Devices, systems and methods for ophthalmic drug delivery. U.S. Patent Application 2007016414, 2007.
73. Avery R, Luttrull J. Intravitreal medicine delivery. U.S. Patent 6, 251, 090, 2001.
74. Li P-Y, Shih J, Lo R et al. An electrochemical intraocular drug delivery device. Sensors and Actuators A: Physical 2008; 143: 41-48.
75. Li P-Y, Sheybani R, Kuo J et al. A parylene bellows electrochemical actuator for intraocular drug delivery. Sensors and Transducers Transducers. Denver, CO, 2009; 2: 1461-1463.
76. Levy B. Intraocular shunt device and method. U.S. Patent Application 20070106200, 2007.
77. Tetz MR, Ries MW, Lucas C et al. Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. Journal of Cataract and Refractive Surgery 1996; 22: 1070-1078.
78. Gilger BC, Davis J, Salmon JH et al. Sustained Release of Celecoxib from Acrylic Intraocular Lenses (IOLs) In Vitro. ARVO, Fort Lauderdale, FL, 2009.
79. Kleinmann G, Apple DJ, Chew J et al. Hydrophilic acrylic intraocular lens as a drug-delivery system for fourth-generation fluoroquinolones. Journal of Cataract and Refractive Surgery 2006; 32: 1717-1721.
80. Tsuchiya Y, Kobayakawa S, Tsuji A et al. Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics. Current Eye Research 2008; 33: 868-875.
81. Eperon S, Bossy-Nobs L, Petropoulos IK et al. A biodegradable drug delivery system for the treatment of postoperative inflammation. International Journal of Pharmaceutics 2008; 352: 240-247.
82. Kugelberg M, Shafiei K, Van Der Ploeg I et al. Intraocular lens as a drug delivery system for dexamethasone. Acta Ophthalmologica 2010; 88: 241-244.
83. Ambati B, Molokhia S, Sant H et al. The Capsule Drug Ring: Novel Platform for Intraocular Delivery. ARVO 2009 Summer Eye Research Conference: Ophthalmic Drug Delivery Systems for the Treatment of Retinal Disease-Basic Research to Clinical Application, Bethesda, MD, 2009.
84. Gilger BC, Salmon JH. Ocular Posterior Segment Drug Distribution from a Single Injection into the Anterior Suprachoroidal Space. Association for Research in Vision and Research, Fort Lauderdale, FL, 2010.
85. Olsen TW, Feng X, Wabner K et al. Cannulation of the suprachoroidal space: a novel drug delivery methodology to the posterior segment. American Journal of Ophthalmology 2006; 142: 777-787.
86. Miller DJ, Li SK, Tuitupou AL et al. Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits. Journal of Ocular Pharmacology and Therapeutics 2008; 24: 385-391.
87. Tang D, Xiao S, Donaldson J et al. Drug Delivery Across the Cornea by PEGylated Liposomes In Vitro and In Vivo. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.
88. Amrite A, Edelhauser H, Singh S et al. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Molecular Vision 2008; 14: 150-160.
89. Adibkia K, Siahi Shadbad M, Nokhodchi A et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. Journal of Drug Targeting 2007; 15: 407-416.
90. Shaunak S. The Therapeutic Potential of Dendrimers in Diseases of the Eye. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2007.
91. De La Fuente M, Seijo B, Alonso M. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Investigative Ophthalmology and Visual Science 2008; 49: 2016-2024.
92. Kester M, Heakal Y, Fox T et al. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Letters 2008; 8: 4116-4121.
93. Bakri SJ, Pulido JS, Mukherjee P et al. Absence of histologic retinal toxicity of intravitreal nanogold in a rabbit model. Retina 2008; 28: 147-149.
94. Guinedi A, Mortada N, Mansour S et al. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. International Journal of Pharmaceutics 2005; 306: 71-82.
95. Greenhalgh K, Turos E. In vivo studies of polyacrylate nanoparticle emulsions for topical and systemic applications. Nanomedicine: Nanotechnology, Biology and Medicine 2009; 5: 46-54.
96. Vandamme T, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. Journal of Controlled Release 2005; 102: 23-28.
97. Crawford K, Korskenyi B, Ruggiero L et al. Nanospheres for Ophthalmic Drug Delivery. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2005.
98. Naash M. Applications of Nanotechnology to Gene Delivery in Ophthalmology. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.
99. Liu J, Min H, Chiodo V et al. Linear Polyethyleneimine-based DNA Nanoparticle Delivery into Mouse Retinas. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.
100. Xu J, Wang Y, Li Y et al. Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model. Journal of Ocular Pharmacology and Therapeutics 2007; 23: 527-539.
101. Prow T, Bhutto I, Kim S et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine 2008; 4: 340-349.
102. Jayagopal A, Russ P, Haselton F. Quantum Dot-based In Vivo Retinal Imaging Of Inflammation. Association for Research in Vision and Ophthalmology, Fort Lauderdale, FL, 2006.